ePrints

A phase I-II study of the oral PARP inhibitor Rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumours

Lookup NU author(s): Dr Yvette DrewORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Kristeleit K, Shapiro GI, Howard HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen L, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R

Publication type: Article

Publication status: Published

Journal: Clinical Cancer Research

Year: 2017

Volume: 23

Issue: 15

Pages: 4095-4106

Print publication date: 01/08/2017

Online publication date: 06/03/2017

Acceptance date: 28/02/2017

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Publisher: American Association for Cancer Research

URL: https://doi.org/10.1158/1078-0432.CCR-16-2796

DOI: 10.1158/1078-0432.CCR-16-2796

PubMed id: 28264872

Altmetrics

Share